Phase I trial of Afatinib intercalated with Carboplatin/Pemetrexed Chemotherapy in advanced non-squamous non-small-cell lung cancer harboring EGFR mutations.

Trial Profile

Phase I trial of Afatinib intercalated with Carboplatin/Pemetrexed Chemotherapy in advanced non-squamous non-small-cell lung cancer harboring EGFR mutations.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Afatinib (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Nov 2017 Status changed from active, no longer recruiting to completed, according to results presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.
    • 06 May 2017 Planned End Date changed from 3 Nov 2016 to 31 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top